Asia-Pacific neurological disorder drugs market is projected to grow at a significant CAGR during the forecast period. The key factors driving the growth of the market include the rising geriatric population, increased prevalence of neurological disorders coupled with the development of novel drugs and technologies for drug development. In the Asia-Pacific region, economies such as China, India, and Japan have a major number of geriatric populations. For instance, Japan has the world’s oldest population, as per the Weforum 2019. The country’s almost a third of its population is over 65; there are 2.3 billion people in their 70s. This population pool serves as a major target audience for the market as this age group is at increased risk of developing neurological disorders.
Asia-Pacific neurological disorder drugs market is segmented on the basis of disorder type into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington disease, and others. Amongst the disorder type segment, Parkinson’s disease segment is projected to hold a lucrative share in the market. The segmental growth of the market is attributed to the increased prevalence of Parkinson’s disease among people across the globe. A broad range of drugs is used for the treatment of neurological disorders, some of which include analgesics, antihypertensive, anticholinergic, hypnotic & sedatives, and others.
To Request a Free Sample of our Asia-Pacific Neurological Disorder Drugs Market: https://www.omrglobal.com/request-sample/asia-pacific-neurological-disorder-drugs-market
Market Coverage
- Market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered- By Disorder Type
- Region Covered- Europe
- Competitive Landscape- Novartis International AG, Allergan Plc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, and F. Hoffmann-La Roche Ltd.
Asia-Pacific Neurological Disorder Drugs Market – Segmentation
By Disorder Type
- Epilepsy
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Huntington Disease
- Others
A full Report of Asia-Pacific Neurological Disorder Drugs Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-neurological-disorder-drugs-market
Asia-Pacific Neurological Disorder Drugs Market – Countries Covered
- China
- India
- Japan
- Rest of Asia-Pacific
Company Profiles
- Alembic Pharmaceuticals Ltd.
- Overview
- Alembic Pharmaceuticals in Neurological Disorder Drug Landscape
- Recent Developments
- Astellas Pharma Inc.
- AstraZeneca Plc
- Cadila Healthcare Ltd.
- Cipla Ltd.
- Daiichi Sankyo Espha Co., Ltd.
- Eisai Co. Ltd.
- GlaxoSmithKline Plc
- Novartis International AG
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Rusan Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-neurological-disorder-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
